Induction of neuronal apoptosis inhibitory protein expression in response to androgen deprivation in prostate cancer

Cancer Letters

Volumn 292, Issue 2, 2010, Pages 176-185

  Chiu, Helen H L ^a   Yong, Theresa M K ^a   Wang, Jun ^a   Wang, Yuwei ^a   Vessella, Robert L ^b   Ueda, Takeshi ^c   Wang, Yu Zhuo ^a   Sadar, Marianne D ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c CHIBA CANCER CENTER   (Japan)

Author keywords

Androgen deprivation; Inhibitors of apoptosis; Neuronal apoptosis inhibitory protein; Nuclear factor B; Prostate cancer

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; NEURONAL APOPTOSIS INHIBITORY PROTEIN; PROSTATE SPECIFIC ANTIGEN; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS; ANDROGEN; MESSENGER RNA;

ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CASTRATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DNA BINDING; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCUS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TRANSCRIPTION REGULATION; CHROMATIN IMMUNOPRECIPITATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANDROGENS; BLOTTING, WESTERN; CASTRATION; CHROMATIN IMMUNOPRECIPITATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEURONAL APOPTOSIS-INHIBITORY PROTEIN; NF-KAPPA B; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 77951885269     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.11.023     Document Type: Article

References (51)

1. Liston P., Fong W.G., Korneluk R.G. The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 2003, 22:8568-8580.
2. Chen Z., Naito M., Hori S., Mashima T., Yamori T., Tsuruo T. A human IAP-family gene, apollon, expressed in human brain cancer cells. Biochem. Biophys. Res. Commun. 1999, 264:847-854.
3. Vucic D., Stennicke H.R., Pisabarro M.T., Salvesen G.S., Dixit V.M. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr. Biol. 2000, 10:1359-1366.
4. Rothe M., Pan M.G., Henzel W.J., Ayres T.M., Goeddel D.V. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 1995, 83:1243-1252.
5. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 1997, 3:917-921.
6. Liston P., Roy N., Tamai K., Lefebvre C., Baird S., Cherton-Horvat G., Farahani R., McLean M., Ikeda J.E., MacKenzie A., Korneluk R.G. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 1996, 379:349-353.
7. Richter B.W., Mir S.S., Eiben L.J., Lewis J., Reffey S.B., Frattini A., Tian L., Frank S., Youle R.J., Nelson D.L., Notarangelo L.D., Vezzoni P., Fearnhead H.O., Duckett C.S. Molecular cloning of ILP-2, a novel member of the inhibitor of apoptosis protein family. Mol. Cell. Biol. 2001, 21:4292-4301.
8. Roy N., Mahadevan M.S., McLean M., Shutler G., Yaraghi Z., Farahani R., Baird S., Besner-Johnston A., Lefebvre C., Kang X., et al. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 1995, 80:167-178.
9. Maier J.K., Lahoua Z., Gendron N.H., Fetni R., Johnston A., Davoodi J., Rasper D., Roy S., Slack R.S., Nicholson D.W., MacKenzie A.E. The neuronal apoptosis inhibitory protein is a direct inhibitor of caspases 3 and 7. J. Neurosci. 2002, 22:2035-2043.
10. Davoodi J., Lin L., Kelly J., Liston P., MacKenzie A.E. Neuronal apoptosis-inhibitory protein does not interact with Smac and requires ATP to bind caspase-9. J. Biol. Chem. 2004, 279:40622-40628.
11. Hunter A.M., Lacasse E.C., Korneluk R.G. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007, 12:1543-1568.
12. Krajewska M., Krajewski S., Banares S., Huang X., Turner B., Bubendorf L., Kallioniemi O.P., Shabaik A., Vitiello A., Peehl D., Gao G.J., Reed J.C. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin. Cancer Res. 2003, 9:4914-4925.
13. Tirro E., Consoli M.L., Massimino M., Manzella L., Frasca F., Sciacca L., Vicari L., Stassi G., Messina L., Messina A., Vigneri P. Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res. 2006, 66:4263-4272.
14. Zhang M., Latham D.E., Delaney M.A., Chakravarti A. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 2005, 24:2474-2482.
15. Nomura T., Yamasaki M., Nomura Y., Mimata H. Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. Oncol. Rep. 2005, 14:993-997.
16. LaCasse E.C., Baird S., Korneluk R.G., MacKenzie A.E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998, 17:3247-3259.
17. Kawakami H., Tomita M., Matsuda T., Ohta T., Tanaka Y., Fujii M., Hatano M., Tokuhisa T., Mori N. Transcriptional activation of survivin through the NF-kappaB pathway by human T-cell leukemia virus type I tax. Int. J. Cancer 2005, 115:967-974.
18. Stehlik C., de Martin R., Kumabashiri I., Schmid J.A., Binder B.R., Lipp J. Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J. Exp. Med. 1998, 188:211-216.
19. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., Baldwin A.S. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281:1680-1683.
20. Chu Z.L., McKinsey T.A., Liu L., Gentry J.J., Malim M.H., Ballard D.W. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc. Natl. Acad. Sci. USA 1997, 94:10057-10062.
21. Dutta J., Fan Y., Gupta N., Fan G., Gelinas C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 2006, 25:6800-6816.
22. Courtois G., Gilmore T.D. Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene 2006, 25:6831-6843.
23. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
24. Suh J., Rabson A.B. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon?. J. Cell. Biochem. 2004, 91:100-117.
25. Sweeney C., Li L., Shanmugam R., Bhat-Nakshatri P., Jayaprakasan V., Baldridge L.A., Gardner T., Smith M., Nakshatri H., Cheng L. Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin. Cancer Res. 2004, 10:5501-5507.
26. Shukla S., Gupta S. Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes. Clin. Cancer Res. 2004, 10:3169-3178.
27. Yemelyanov A., Gasparian A., Lindholm P., Dang L., Pierce J.W., Kisseljov F., Karseladze A., Budunova I. Effects of IKK inhibitor PS1145 on NF-kappaB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells. Oncogene 2006, 25:387-398.
28. Huerta-Yepez S., Vega M., Garban H., Bonavida B. Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis. Clin. Immunol. 2006, 120:297-309.
29. Kucharczak J., Simmons M.J., Fan Y., Gelinas C. To be, or not to be: NF-kappaB is the answer - role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 2003, 22:8961-8982.
30. Sadar M.D., Akopian V.A., Beraldi E. Characterization of a new in vivo hollow fiber model for the study of progression of prostate cancer to androgen independence. Mol. Cancer Ther. 2002, 1:629-637.
31. Wang Y., Xue H., Cutz J.C., Bayani J., Mawji N.R., Chen W.G., Goetz L.J., Hayward S.W., Sadar M.D., Gilks C.B., Gout P.W., Squire J.A., Cunha G.R., Wang Y.Z. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab. Invest. 2005, 85:1392-1404.
32. Bissery M.C., Guenard D., Gueritte-Voegelein F., Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 1991, 51:4845-4852.
33. Andrews N.C., Faller D.V. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 1991, 19:2499.
34. Stamey T.A., Yang N., Hay A.R., McNeal J.E., Freiha F.S., Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl. J. Med. 1987, 317:909-916.
35. Kellokumpu-Lehtinen P., Nurmi M., Koskinen P., Irjala K. Prostate-specific antigen as a marker of adenocarcinoma of prostate. Urol. Res. 1989, 17:245-249.
36. Liu Y., Denlinger C.E., Rundall B.K., Smith P.W., Jones D.R. Suberoylanilide hydroxamic acid induces Akt-mediated phosphorylation of p300, which promotes acetylation and transcriptional activation of RelA/p65. J. Biol. Chem. 2006, 281:31359-31368.
37. Cinar B., Yeung F., Konaka H., Mayo M.W., Freeman M.R., Zhau H.E., Chung L.W. Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells. Biochem. J. 2004, 379:421-431.
38. Palvimo J.J., Reinikainen P., Ikonen T., Kallio P.J., Moilanen A., Janne O.A. Mutual transcriptional interference between RelA and androgen receptor. J. Biol. Chem. 1996, 271:24151-24156.
39. Maier J.K., Balabanian S., Coffill C.R., Stewart A., Pelletier L., Franks D.J., Gendron N.H., Mackenzie A.E. Distribution of neuronal apoptosis inhibitory protein in human tissues. J. Histochem. Cytochem. 2007, 55:911-923.
40. Poma P., Notarbartolo M., Labbozzetta M., Sanguedolce R., Alaimo A., Carina V., Maurici A., Cusimano A., Cervello M., D'Alessandro N. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production. Int. J. Oncol. 2006, 28:923-930.
41. Notarbartolo M., Cervello M., Poma P., Dusonchet L., Meli M., D'Alessandro N. Expression of the IAPs in multidrug resistant tumor cells. Oncol. Rep. 2004, 11:133-136.
42. Chen Q., Baird S.D., Mahadevan M., Besner-Johnston A., Farahani R., Xuan J., Kang X., Lefebvre C., Ikeda J.E., Korneluk R.G., MacKenzie A.E. Sequence of a 131-kb region of 5q13.1 containing the spinal muscular atrophy candidate genes SMN and NAIP. Genomics 1998, 48:121-127.
43. Sandelin A., Wasserman W.W., Lenhard B. ConSite: web-based prediction of regulatory elements using cross-species comparison. Nucleic Acids Res. 2004, 32:W249-252.
44. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., Oudard S., Theodore C., James N.D., Turesson I., Rosenthal M.A., Eisenberger M.A. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl. J. Med. 2004, 351:1502-1512.
45. Watson R.W., Fitzpatrick J.M. Targeting apoptosis in prostate cancer: focus on caspases and inhibitors of apoptosis proteins. BJU Int. 2005, 96(Suppl. 2):30-34.
46. Altieri D.C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003, 22:8581-8589.
47. D'Antonio J.M., Ma C., Monzon F.A., Pflug B.R. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence. Prostate 2008, 68:698-714.
48. Romanish M.T., Lock W.M., van de Lagemaat L.N., Dunn C.A., Mager D.L. Repeated recruitment of LTR retrotransposons as promoters by the anti-apoptotic locus NAIP during mammalian evolution. PLoS Genet. 2007, 3:e10.
49. Perkins N.D. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene 2006, 25:6717-6730.
50. Dziarmaga A., Hueber P.A., Iglesias D., Hache N., Jeffs A., Gendron N., Mackenzie A., Eccles M., Goodyer P. Neuronal apoptosis inhibitory protein is expressed in developing kidney and is regulated by PAX2. Am. J. Physiol. 2006, 291:F913-920.
51. Xu M., Okada T., Sakai H., Miyamoto N., Yanagisawa Y., MacKenzie A.E., Hadano S., Ikeda J.E. Functional human NAIP promoter transcription regulatory elements for the NAIP and PsiNAIP genes. Biochim. Biophys. Acta. 2002, 1574:35-50.